Sponsor or institution
Clinical trials and research at Hebei Senlang Biotechnology Inc., Ltd.
As of November 12, 2026, Find a Trial lists 6 clinical trials run by Hebei Senlang Biotechnology Inc., Ltd. that are recruiting, in China. By phase: Phase 1 (2), Phase 2 (1), Early Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Autologous CAR-T cell treatment for refractory and relapsing ulcerative colitis | Early Phase 1 | Guangzhou | Recruiting | Feb 27, 2026 |
| Senl_B19 (S1904) CD19 CAR-T for relapsed or refractory CD19+ B-ALL in children and young adults | Phase 2 | Beijing | Recruiting | Nov 24, 2025 |
| CAR-T therapy for adults with relapsed or refractory T-lymphoblastic lymphoma or leukemia | Phase 1 | Shanghai | Recruiting | Nov 18, 2023 |
| Treatment of relapsed T-cell leukemia with Senl-T7 CAR T cells | — | Beijingcun, Hebei | Recruiting | Nov 23, 2022 |
| CAR-T cell therapy for relapsed or treatment-resistant blood cancers | — | Taiyuan, Shanxi | Recruiting | Nov 16, 2022 |
| Using dual-target CAR T cells to treat B cell blood cancers | Phase 1 | Wuhan, Hubei | Recruiting | May 24, 2022 |
All recruiting trials (6)
-
Autologous CAR-T cell treatment for refractory and relapsing ulcerative colitis
This study will try autologous CAR‑T cell injections to see if they can bring 12‑week clinical remission in people with moderate‑to‑severe ulcerative colitis who have not responded to approved treatments.
-
Senl_B19 (S1904) CD19 CAR-T for relapsed or refractory CD19+ B-ALL in children and young adults
This trial will test S1904 (Senl_B19) CD19 CAR-T cells in children and young adults aged 3–25 with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia.
-
CAR-T therapy for adults with relapsed or refractory T-lymphoblastic lymphoma or leukemia
This study is testing a new CAR-T therapy called SENL101 to see if it can help adults with hard-to-treat T-lymphoblastic lymphoma or leukemia feel better and improve their health.
-
Treatment of relapsed T-cell leukemia with Senl-T7 CAR T cells
This study is testing a new type of CAR T cell treatment to see if it can help people with relapsed or hard-to-treat T-cell leukemia feel better.
-
CAR-T cell therapy for relapsed or treatment-resistant blood cancers
This trial will test whether an autologous CAR-T cell infusion is safe and tolerable for people ages 14–75 with relapsed or refractory leukemia, lymphoma, or multiple myeloma whose tumors express CD19, CD20, or BCMA.
-
Using dual-target CAR T cells to treat B cell blood cancers
This study is testing a new type of CAR T-cell therapy that targets multiple markers to see if it can help people with tough-to-treat B cell blood cancers.
Quick answers
How many clinical trials run by Hebei Senlang Biotechnology Inc., Ltd. are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2, Phase 2: 1, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.